MGNX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
32.8M
+58.0%
20.8M
-49.6%
41.2M
-43.4%
72.8M
+960.4%
6.9M
Cost of Revenue
0
-100.0%
9.5M
-5.8%
10.1M
-12.7%
11.6M
0
Gross Profit
32.8M
+192.0%
11.2M
-63.9%
31.1M
-49.2%
61.3M
+791.7%
6.9M
Operating Expenses
46.7M
+4.5%
44.7M
+3.4%
43.2M
+1.4%
42.6M
-14.9%
50.1M
R&D
38.8M
+10.9%
35.0M
+2.9%
34.0M
+3.9%
32.7M
-19.8%
40.8M
SG&A
7.9M
-18.6%
9.7M
+5.1%
9.2M
-6.8%
9.9M
+6.5%
9.3M
Operating Income
-13852000
+58.6%
-33439000
-176.4%
-12097000
-164.9%
18.6M
+143.1%
-43224000
EBITDA
-13144000
+58.6%
-31752000
-205.5%
-10392000
-150.9%
20.4M
+149.4%
-41317000
Net Income
19.5M
+153.1%
-36774000
-159.8%
-14155000
-184.1%
16.8M
+146.4%
-36251000
EPS (Basic)
$0.31
+153.4%
$-0.58
-163.6%
$-0.22
-181.5%
$0.27
+147.4%
$-0.57
EPS (Diluted)
$0.31
+153.4%
$-0.58
-163.6%
$-0.22
-181.5%
$0.27
+147.4%
$-0.57
Shares (Diluted)
63.6M
+0.2%
63.4M
+0.3%
63.2M
-0.1%
63.3M
+0.2%
63.1M
MacroGenics (MGNX) โ€” Financials